Fenofibrate promotes erucic acid metabolism by peroxisome enzyme EHHADH activation alleviating high-fat diet–induced steatotic liver disease
- 16 May 2025
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 107 (7) , 100047
Abstract
No abstract availableKeywords
Funding Information
- Jiangsu Province Natural Science Foundation (BK20210430)
- National Natural Science Foundation of China (81773827, 82304642)
- China Pharmaceutical University
- Double First Class University Plan (CPU2018GY33)
- China Postdoctoral Science Foundation (2020M681786)
This publication has 28 references indexed in Scilit:
- NAFLD and NASH: etiology, targets and emerging therapiesDrug Discovery Today, 2024
- Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver DiseaseMolecular Pharmaceutics, 2022
- Impact of fenofibrate on NAFLD/NASH: A genetic perspectiveDrug Discovery Today, 2022
- Serum concentration of fatty acids in children with obesity and nonalcoholic fatty liver diseaseNutrition, 2022
- Epidemiological Features of NAFLD From 1999 to 2018 in ChinaHepatology, 2020
- Molecular pathways of nonalcoholic fatty liver disease development and progressionCellular and Molecular Life Sciences, 2018
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver diseaseCellular and Molecular Life Sciences, 2018
- Triglyceride Metabolism in the LiverComprehensive Physiology, 2018
- A conjugated fatty acid present at high levels in bitter melon seed favorably affects lipid metabolism in hepatocytes by increasing NAD+/NADH ratio and activating PPARα, AMPK and SIRT1 signaling pathwayThe Journal of Nutritional Biochemistry, 2016
- Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver DiseaseDigestive Diseases and Sciences, 2016